Medicinal Wolverine

REFERENCES

BPC-157 TB-500 References: The Cited Record

Every constituent study and FDA source cited across this Wolverine-blend digest, indexed by number, with DOIs, PubMed identifiers, and FDA page URLs.

Back to the researchLegal & access status

How to read this list

These are the BPC-157 TB-500 references behind every quantitative claim on this site. Numbers [1]-[12] are peer-reviewed studies and reviews on the two constituents; numbers [13]-[16] are FDA pages supporting the regulatory and access statements on the legal-status page. Each entry carries a DOI or PubMed identifier where one exists, or a direct FDA URL.

Two standing caveats apply across the list. First, most efficacy data labeled "TB-500" were generated with full-length Thymosin Beta-4, not the Ac-LKKTETQ heptapeptide [4][8]. Second, no entry here is a controlled study of the BPC-157 + TB-500 combination, because none has been published [9]. The full citations follow in the reference index below.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  5. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. ↗
  6. Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10:17078. ↗
  7. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. ↗
  8. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
  9. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
  10. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  11. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  12. Ruff D, et al. Safety and pharmacokinetics of intravenous thymosin beta 4 (Phase 1 single-dose escalation study); and 2021 first-in-human study of full-length thymosin beta-4. Reported human single-agent data for full-length Thymosin Beta-4, not the TB-500 heptapeptide. ↗
  13. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Lists BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' as 503A Category 2 substances (entries effective with the September 29, 2023 update). FDA, verified 2026-05-29. ↗
  14. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Definitions of Category 1 and Category 2, the 503A/503B framework, and the bulks-list nomination process. FDA, verified 2026-05-29. ↗
  15. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Public calendar listing BPC-157, KPV, TB-500, and MOTs-C as bulk drug substances 'being considered for inclusion on the 503A Bulks List' to be discussed at this scheduled meeting (a scheduled discussion, not a decision). FDA, verified 2026-05-29. ↗
  16. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (guidance landing page); and FDA compounding pages describing the licensed-prescriber-to-503A/503B access pathway and ingredient-eligibility rules. FDA, verified 2026-05-29. ↗